Laserfiche WebLink
Evidence- informed residential services programs, as noted below <br />3. Expand telehealth to increase access to treatment for OUD and any co-occurring <br />suD/MH conditions, co-usage, and/or co-addiction, including MAT, as well as <br />counseling, psychiatric support, and other treatment and recovery support services. <br />4. lmprove oversight of opioid Treatment Programs {OTPs} to assure evidence-based, <br />evidence-informed, or promising practices such as adequate methadone dosing. <br />5. Support mobile intervention, treatment, and recovery services, offered by qualified <br />professional and service providers, such as peer recovery coaches, for persons with <br />OUD and any co-occurring 5UD/MH conditions, co-usaBe, and/or co-addiction and for <br />persons who have experienced an opioid overdose. <br />6' Support treatment of mental health trauma resulting from the traumatic experiences <br />of the opioid user (e.g., violence, sexual assault, human trafficking or adverse <br />childhood experiences) and family members (e.g., surviving family members after an <br />overdose or overdose fatality), and training of health care personnel to identify and <br />address such trauma. <br />7. support detoxification (detoxJ and withdrawal management services for persons with <br />OUD and any co-occurring SUD/MH conditions, co-usage, andf or co-addiction, <br />including medical detox, referral to treatment, or connections to other services or <br />supports. <br />8' Support training on MAT for health care providers, students, or other supporting <br />professionals, such as peer recovery coaches or recovery outreach specialists, <br />including telementoring to assist community-based providers in rural or underserved <br />areas. <br />9. Support workforce development for addiction professionals who work with persons <br />with OUD and any co-occurring SUD/MH conditions, co-usage, and/or co-addiction. <br />10' Provide fellowships for addiction medicine specialists for direct patient care, <br />instructors, and clinical research for treatments. <br />11. Provide funding and training for clinicians to obtain a waiver under the federal Drug <br />Addiction Treatment Act of 2000 (DATA 2000) to prescribe MAT for OUD, and provide <br />technical assistance and professional support to clinicians who have obtained a DATA <br />2000 waiver. <br />12. Support the dissemination of web-based training curricula, such as the American <br />Academy of Addiction Psychiatry's Provider Clinical Support Service-Opioids web- <br />based training curriculum and motivational interviewing. <br />13. Support the development and dissemination of new curricula, such as the American <br />Academy of Addiction Psychiatry's Provider Clinical Support Service for Medication- <br />Assisted Treatment. <br />B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY